Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?

27 Nov 2020

Abstract excerpt

kinase domain (KD) mutation testing have a well consolidated role in the routine management of chronic myeloid leukemia (CML) patients, as they provide precious information for therapeutic decision-making. Molecular response levels are used to define whether a patient has an "optimal", "warning", or "failure" response to tyrosine kinase inhibitor (TKI) therapy. Mutation status may be useful to decide whether TKI...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33261150
DOI: 10.3390/jcm9123865

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?PMID 33261150Read ↗

From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care.Semantic proximity Read ↗

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper.Semantic proximity Read ↗

Molecular monitoring of chronic myeloid leukemia: present and future.Semantic proximity Read ↗

Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic ApproachesSemantic proximity Read ↗

Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE studySemantic proximity Read ↗

Digital PCR for BCR‐ABL1 Quantification in CML: Current Applications in Clinical PracticeSemantic proximity Read ↗

Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia PatientsSemantic proximity Read ↗

Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study.Semantic proximity Read ↗

Molecular monitoring in CML: how deep? How often? How should it influence therapy?Semantic proximity Read ↗

Present and future of molecular monitoring in chronic myeloid leukaemia.Semantic proximity Read ↗

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.Semantic proximity Read ↗

Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.